Received: 12 August 2021
Accepted: 28 December 2021
First Online: 8 January 2022
: This retrospective de-identified study was approved by the HEMORIO Ethics Committee as secondary use of already existing data with a waiver of consent from participants.
: Not applicable.
: Clarisse Lobo received funds from the Pfizer Healthcare Foundation to conduct this work. Jane S. Hankins receives consulting fees from Forma Therapeutics, Global Blood Therapeutics, and bluebird bio. Remaining authors do not have any competing interest to declare.